“Project BioShield” Model Could Apply More Broadly, FDA Commissioner Says
Executive Summary
"Project BioShield" offers a model that policymakers should consider to encourage research in infectious diseases, FDA Commissioner McClellan told the Commonwealth Club in San Francisco June 9
You may also be interested in...
R&D “Pull” Incentives For Vaccines Need $250 Mil. Guarantee – Brookings
Incentive programs to encourage development of vaccines for diseases of the developing world would need to ensure a market of $250 mil.-$500 mil. to be effective, Brookings Institution Senior Fellow Michael Kremer, PhD, said
R&D “Pull” Incentives For Vaccines Need $250 Mil. Guarantee – Brookings
Incentive programs to encourage development of vaccines for diseases of the developing world would need to ensure a market of $250 mil.-$500 mil. to be effective, Brookings Institution Senior Fellow Michael Kremer, PhD, said
Labeling And Liability: FDA Wary Of “Over-Warning,” “Piling On” By Lawyers
Trial lawyers should work with FDA to focus product liability actions on cases where manufacturers appear to be withholding information, Commissioner McClellan suggested during the National Community Pharmacists Association legislative conference May 19 in Washington, D.C